# Mulligan BioCapital

> Mulligan BioCapital is a VC fund in Hamburg backing Medical, Biotechnology and Health Care. See 5 investments, round sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Hamburg, Germany
- Total investments: 5
- Last investment: Oct 2007
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.mulliganbio.com

Mulligan BioCapital is an investment firm dedicated to the life sciences with a specific focus on biotechnology with health care applications.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 60% |
| Biotechnology | 3 | 60% |
| Health Care | 2 | 40% |
| Genetics | 1 | 20% |
| Biopharma | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Seed | 1 | 20% |
| Series C | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 3 | 60% |
| Switzerland | 1 | 20% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DIREVO Industrial Biotechnology | DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaderssuch as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors. | $16.8M | Series C | Oct 18, 2007 |  |
| Spinal Cord Therapeutics GmbH | Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system. | $14M | Series A | Sep 19, 2005 |  |
| 4-Antibody AG | 4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also developspreclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.4-Antibody AG was founded in 2002 and is based in Basel, Switzerland. | $3.3M | Seed | Mar 17, 2004 |  |
| Cardion | Cardion is a biopharmaceutical company that integrates synergistic local gene delivery, stem cell engineering, and tolerance induction capabilities to build cardiovascular gene therapy products. Cardion was founded in 1996 and is based in Erkrath, Nordrhein-Westfalen. | $12.6M |  | Sep 23, 2002 |  |
| DIREVO Industrial Biotechnology | DIREVO provides customized solutions for various industries via the development and optimization of biocatalysts with its proprietary ultra-high-throughput screening platform. Serving the Feed & Food industries and chemical / biorefinery businesses, DIREVO products are developed either independently or in conjunction with global leaderssuch as Genencor (a division of Danisco A/S), AB Enzymes, Roal Ltd. and Nestlé. DIREVO Industrial Biotechnology GmbH is privately owned and located in Cologne, Germany. The shareholders include Wölbern EquityPartner GmbH (Hamburg), NRW Bank (Düsseldorf), TVM Capital (Munich), Danisco A/S (Copenhagen), a private equity firm affiliated with Sparkasse KölnBonn (Cologne), SandersMorrisHarris EnzymesLLC (New York), Mulligan BioCapital (Hamburg), and several private investors. | $9.7M | Series A | Dec 18, 2000 |  |

5 of 5 investments shown.

## Co-investors
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 2 deals together
- [Techno Venture Management](https://shizune.co/investors/profile/tvm-techno-venture-management) — VC Fund, 2 deals together
- [Bankhaus Wölbern](https://shizune.co/investors/profile/bankhaus-wlbern) — VC Fund, 1 deal together
- [Danisco A/S](https://shizune.co/investors/profile/danisco-a-s) — VC Fund, 1 deal together
- [Deutsche Venture Capital](https://shizune.co/investors/profile/deutsche-venture-capital) — VC Fund, 1 deal together
- [FNI Venture Capital](https://shizune.co/investors/profile/fni-venture-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Switzerland](https://shizune.co/investors/medical-vc-funds-switzerland)

## FAQ

### What does Mulligan BioCapital invest in?

Mulligan BioCapital invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Mulligan BioCapital last invest?

The most recent investment recorded for Mulligan BioCapital closed in Oct 2007. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co